Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

5.550 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	11
Open	5.550
Bid (Size)	5.390 (500)
Ask (Size)	5.750 (200)
Prev. Close	5.550
Today's Range	5.550 - 5.550
52wk Range	4.910 - 18.00
Shares Outstanding	95,568,307
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Rosen Law Firm Urges ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

August 06, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

SPRY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

August 06, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

Performance

YTD	-51.7%	-51.7%
1 Month	-32.2%	-32.2%
3 Month	-38.3%	-38.3%
6 Month	-42.6%	-42.6%
1 Year	-69.1%	-69.1%

More News

Shareholder Notice: Robbins LLP Informs Investors of the ARS Pharmaceuticals Inc. Class Action

August 05, 2026

From Robbins LLP

Via Business Wire

ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results

August 03, 2026

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment ↗

May 15, 2026

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

July 21, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

July 14, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

July 07, 2026

From Pomerantz LLP

Via GlobeNewswire

ARS Pharmaceuticals Announces CEO Succession

July 07, 2026

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud

July 01, 2026

From Levi & Korsinsky, LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

June 30, 2026

From Pomerantz LLP

Via GlobeNewswire

SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

June 28, 2026

From The Schall Law Firm

Via Business Wire

Which stocks are moving before the opening bell on Thursday? ↗

June 25, 2026

Via Chartmill

These stocks are moving in today's after hours session ↗

June 24, 2026

Via Chartmill

ARS Pharmaceuticals Provides Commercial and Financial Updates

June 24, 2026

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies

June 04, 2026

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharma (SPRY) Q1 2026 Earnings Transcript ↗

May 18, 2026

Via The Motley Fool

ARS Pharma (SPRY) Q4 2025 Earnings Transcript ↗

May 15, 2026

Via The Motley Fool

ARS Pharmaceuticals Q1 Earnings Call Highlights ↗

May 15, 2026

Via MarketBeat

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

May 15, 2026

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

May 15, 2026

Via Benzinga

ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President

May 13, 2026

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results

May 07, 2026

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

April 15, 2026

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label

March 27, 2026

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is ARS Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, ARS Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does ARS Pharmaceuticals, Inc. - Common Stock trade on?

ARS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock is SPRY on the Nasdaq Stock Market

What is the current price of ARS Pharmaceuticals, Inc. - Common Stock?

The current price of ARS Pharmaceuticals, Inc. - Common Stock is 5.550

When was ARS Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of ARS Pharmaceuticals, Inc. - Common Stock was at 08/06/26 04:00 PM ET

What is the market capitalization of ARS Pharmaceuticals, Inc. - Common Stock?

The market capitalization of ARS Pharmaceuticals, Inc. - Common Stock is 530.40M

How many shares of ARS Pharmaceuticals, Inc. - Common Stock are outstanding?

ARS Pharmaceuticals, Inc. - Common Stock has 530M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.